Jefferies Reiterates Buy Rating on Roivant Sciences (ROIV) amid Brepocitinib NDA acceptance
Tweet Send to a Friend
Jefferies analyst Dennis Ding reiterated a Buy rating and $30.00 price target on Roivant Sciences (NASDAQ: ROIV)The analyst commented, "Brepo's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
